Compare SKYX & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SKYX | AARD |
|---|---|---|
| Founded | 2004 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.3M | 165.8M |
| IPO Year | 2014 | N/A |
| Metric | SKYX | AARD |
|---|---|---|
| Price | $1.18 | $6.35 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $5.00 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 1.9M | 439.3K |
| Earning Date | 05-13-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,700,948.00 | N/A |
| Revenue This Year | $25.12 | N/A |
| Revenue Next Year | $24.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 9.78 | N/A |
| 52 Week Low | $0.95 | $3.35 |
| 52 Week High | $3.29 | $17.94 |
| Indicator | SKYX | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 54.05 | 58.05 |
| Support Level | $1.00 | $4.76 |
| Resistance Level | $1.29 | $11.37 |
| Average True Range (ATR) | 0.10 | 0.93 |
| MACD | 0.02 | 0.12 |
| Stochastic Oscillator | 65.16 | 52.06 |
SKYX Platforms Corp operates in the business of developing proprietary technology that enables a quick and safe installation of electrical fixtures, such as light fixtures and ceiling fans. Its technology consists of a weight-bearing, fixable socket and a revolving plug for conducting electric power and supporting an electrical appliance attached to a wall or ceiling. The socket is comprised of a nonconductive body that houses conductive rings connectable to an electric power supply through terminals in its side exterior. The plug is also comprised of a nonconductive body that houses corresponding conductive rings, attaches to the socket via a male post, and is capable of feeding electric power to an appliance. It generates its income from lighting and heating products sold in the USA.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.